Skip to main content
Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze 6578 達邦蛋白. Please read: https://finlab.finance/en/setup?stock=6578

No install, open FinLab Studio

6578

達邦蛋白 AgriTech As of 2026-06-17 Updated daily after market close

quality needs a look, premium valuation.

1 active signal
Revenue ≥20%
This page refreshes daily after the close. Add 達邦蛋白 to your watchlist to track signal changes on your next visit.
Valuation 45Quality 31Growth 71Momentum 21Chips 15

Is 達邦蛋白 a buy? Fundamentals and valuation first

  • Weak profitability.Operating margin is in the 30th market percentile. Latest quarterly ROE ≈ 0.6%.

  • Valuation is high.PE is in the 97th market percentile.

  • Foreign investors are net selling.Foreign 20-day net flow ≈ -3.5% of volume (net sell).

  • Strong revenue growth.Latest monthly revenue YoY ≈ 27.2%, above the 20% growth threshold.

  • Signals are active now.On the latest data, signals such as Revenue YoY ≥ 20% are active — see the historical forward returns after each occurrence below.

Chip flow

Bullish +0.66
BearishNeutralBullish

Single-sided accumulation, concentration rising — bullish

  • Single-sided accumulation, concentration rising — bullish
  • 國泰-高雄 holds 816 lots
  • sellers have 254 lots left, ~85 sessions to clear

Window from 2026-01-17 · Price -16% · branches to 2026-06-17· TDCC to 2026-06-12

  • Largest holder 國泰-高雄 has accumulated 816 lots since the start (sold 1%), holding.
  • Main distributor 第一金-台中 peaked at 254 lots, has sold 48%, 133 left, ~40 sessions to clear at the recent pace.
  • TDCC big holders (absolute) >1000-lot holders +1.15pp, mid holders +1, retail -1.31pp — concentration shifting upward.
  • Foreign hedge-desk net short Net short -242 lots (inferred from branch profile, mostly hedging — not necessarily bearish, not case-confirmed).
Branch inventory reconstruction
Accumulating holders Branches that accumulated shares during the window and still hold positive inventory; they are the absorbing side.
Distributing sellers Branches that built inventory earlier and have been selling it down; the remaining number estimates what has not cleared.
Net-short desks Trading-desk branches with negative inventory or net selling, often hedge, offsetting, or short-term flow. It is not automatically a bearish view.
Accumulating
國泰-高雄第一金-高雄玉山-左營永豐金-南京聯邦-忠孝台新-嘉義
Distributing
第一金-台中台中銀-員林永豐金-永康富邦-台中元大-斗六日茂
Desks
own scale
兆豐-台南兆豐-忠孝新光凱基-台北
Price Accumulating & Distributing share one scale (comparable); Desks is independent. Zero is the baseline
Branch details Unit: lots

Accumulating

  • 國泰-高雄 +816
    sold 1%
  • 第一金-高雄 +482
    sold 0%
  • 玉山-左營 +434
    sold 0%· still adding
  • 永豐金-南京 +355
    sold 0%
  • 聯邦-忠孝 +336
    sold 0%· still adding
  • 台新-嘉義 +174
    sold 0%· still adding

Distributing

  • 第一金-台中 133 left
    sold 48%· ~40 sessions to clear
  • 台中銀-員林 18 left
    sold 65%· ~23 sessions to clear
  • 永豐金-永康 37 left
    sold 29%· ~62 sessions to clear
  • 富邦-台中 29 left
    sold 26%· paused recently
  • 元大-斗六 20 left
    sold 46%· ~29 sessions to clear
  • 日茂 10 left
    sold 70%· paused recently

Desks

  • 兆豐-台南 -1,676
    unclassified
  • 兆豐-忠孝 -516
    unclassified
  • 新光 -243
    unclassified
  • 凱基-台北 -240
    day-trade · selling pressure
Still selling 254 lots ~85 sessions to bottom at most
Recent buy/sell force +489 absorbed / -82 sold buyers slightly ahead
Hedge-desk net short -2 lots potential cover-buying, not selling pressure
TDCC big holders · absolute-holding cross-check
>1000-lot holder share Retail (<400 lots) share Price (right axis)

Direction matches: big-holder share rose while retail share fell.

Describes chip flow, not investment advice. Branch data discloses only high-volume branches with ~1-day lag; TDCC is weekly. Inventory is a relative reconstruction from the window start, not absolute holdings.

Historical evidence

Signals active now

These signals are true on the latest data, with this stock's own historical forward-return stats after each occurrence.

Monthly revenue YoY ≥ 20% (from filing deadline)

Active · now 27.21%

Monthly revenue YoY ≥ 20%; event date is the first trading day after the filing deadline (no look-ahead).

26 historical occurrences (since 2018-09-18)
Average forward return after Monthly revenue YoY ≥ 20% (from filing deadline)。20-day: Win 65%, Sample 20, Median +3.81%, Excess +1.11%, Beat mkt rate 45%；60-day: Win 47.4%, Sample 19, Median -1.59%, Excess -5.76%, Beat mkt rate 26.3%；120-day: Win 29.4%, Sample 17, Median -1.94%, Excess -14.38%, Beat mkt rate 17.6%

120 days after: historical avg -3.11%

20-day +4.8%
60-day +2.16%
120-day -3.11%
20-day
60-day
120-day
Win
65%
47.4%
29.4%
Sample
20
19
17
Median
+3.81%
-1.59%
-1.94%
Excess
+1.11%
-5.76%
-14.38%
Beat mkt rate
45%
26.3%
17.6%

Over 17 occurrences, 120-day forward avg declined 3.11%, lagged the market by 14.38 pts; win rate 29.4%.

Does this signal hold up across the market

Over the past 242 months, on average ~404 stocks per month met “monthly revenue YoY ≥ 20%”; their adjusted-close return over the next 60 trading days averaged 6.94% (equal-weighted), beating the market by 2.37 points on average, and outperformed the TAIEX total-return index in 64.5% of months.

Each month, equal-weighted 60-day forward adjusted return of all signal-matching stocks, then averaged across months; excess vs the TAIEX total-return index.

Signals not active (historical stats for reference)

These are not occurring now; historical samples shown for comparison.

252-day price high (breakout)

Pending

Adjusted close makes a new 252-day high; repeats within 20 days counted once.

7 times historically; 60-day forward avg -5.48%, win rate 42.9%, beating the market by -11.07 pts on average.

Foreign net buying for 5 straight days

Pending

Foreign net flow (ex-dealer) positive for 5 straight days; event on day 5; repeats within 20 days counted once.

17 times historically; 60-day forward avg +4.26%, win rate 52.9%, beating the market by +0.83 pts on average.

What does 達邦蛋白 do? Company profile

農業科技；動物營養、飼料原料、功能性飼料添加劑與精準發酵 CDMO/ODM/OEM 上櫃（櫃買中心）

Overview

6578 對應證券為上櫃普通股「達邦蛋白」，公司全名為達邦蛋白生技股份有限公司，英文名 DaBomb Protein Biotech Corp.。公司成立於 2001-12-28，總部位於台南市安南區工業三路 52 號，2018-09-18 掛牌上櫃。依 2025 年報與公開資訊，公司於 2023 年 12 月更名為達邦蛋白生技股份有限公司。2025 年報列示流通在外記名普通股 71,941,901 股，額定股本 100,000,000 股；公開資料另列近月公司登記實收資本額 719,419,010 元，與流通在外股數一致。2025 年報顯示，2025-10-07 董事會解任劉郁芬總經理並選任陳威辰擔任總經理，2025-10-31 劉郁芬辭任董事長及董事，陳威辰接任董事長；截至 2026 年股東會資料，董事長及總經理均為陳威辰。員工規模：2025 年直接人員 18 人、間接人員 29 人，合計 47 人，平均年齡 38.5 歲，平均服務年資 6.39 年。主要股東（2026-03-24）：國歡企業有限公司 19,263,064 股、26.78%；陳威辰 6,479,046 股、9.01%；百世共好有限公司 3,668,000 股、5.10%；國菁企業有限公司 2,500,000 股、3.48%；嘉贏投資有限公司 2,088,303 股、2.90%。

Business

達邦蛋白以微生物整合工程、乳酸菌水解與精準發酵為核心，主要產品用於水產、畜產養殖之蛋白質原料與功能性保健產品。2025 年營收 309,335 千元，較 2024 年 337,824 千元減少 8.43%；2025 年稅後淨損 69,338 千元、EPS -0.96 元，主要受到匯率波動、營業費用與營業外損失影響。2025 年產品營收結構為：水解黃豆胜肽蛋白 200,984 千元、65%；動物益生菌 99,414 千元、32%；其他 8,937 千元、3%。相較 2024 年水解黃豆胜肽蛋白 89%、動物益生菌 11%，功能性添加劑比重已明顯提高。銷售區域：2025 年台灣 82,503 千元、27%；東南亞 130,866 千元、43%；其他 95,966 千元、30%；公司年報稱主要以外銷為主，客戶遍及中國、南韓、日本、菲律賓、柬埔寨、越南、馬來西亞，且越南市場市占率領先其他同業。商業模式包括自有品牌/自有技術生產植物性胜肽蛋白、後生元與動物益生菌產品，並發展 CDMO、ODM、OEM，服務內容涵蓋菌株篩選、發酵優化、製程設計、後段加工、配方開發與量產交付。主要銷售對象為飼料廠、畜牧及水產養殖業者、區域經銷商或代理商；年報揭露重要客戶但以甲、乙、丙客戶匿名，未揭露實名。

Outlook 2025–2028

2025 至 2028 展望可分為成長動能、技術/產能、產業趨勢與風險。成長動能：公司 2025 年營收雖下滑，但高附加價值產品拉升營運表現，動物益生菌占比由 2024 年 11% 升至 2025 年 32%；2026 年 1-5 月累計營收 154,341 千元，年增 15.6%，顯示短期營收已有回升跡象。公司在 2026 年啟動雙發展引擎：一是自有研發產品線，包括植物性優質胜肽蛋白與 ProBioSyntec 胜肽益生菌生物整合工程所開發的後生元系列；二是 CDMO/ODM/OEM，以精準發酵技術與配方設計代工取得品牌商與動物營養企業合作機會。技術與產能：2024-2025 年公司將生產基地拉回台灣，除固態發酵外新增精準液態發酵；2025 年報稱將逐步擴大 CDMO 客戶並修整胜肽蛋白生產設備以提高稼動率。研發方向包括高濃度乳酸菌後生元精準發酵製程成本優化、飼料原料免疫功能提升、飼料添加劑、寵物保健產品、農業用益生菌、養殖用益生菌、副產物再利用、原料微生物醱酵等；2026 年預計研發費用 10,661 千元。產業趨勢：全球無抗養殖、食安、環保、魚粉替代、植物性蛋白、後生元/益生菌、寵物保健及精準動保需求有利公司產品定位。主要風險：水解黃豆胜肽蛋白市場競爭者增加且可能以低價競爭；豆粉/豆粕等大宗原物料價格波動；外銷比率超過 70%，美元匯率波動會影響損益；越南仍為重要外銷市場，存在區域集中風險；非洲豬瘟、氣候異常、關稅與全球貿易政策會干擾客戶下單與出貨；CDMO/ODM/OEM 需持續取得客戶與量產驗證，實際貢獻仍待追蹤。2027-2028 的具體財務預測公司未公開，以上展望屬依年報、月營收與產業趨勢推估。

Supply Chain

Upstream
  • 黃豆豆粉／豆粕與大宗穀物原料供應商 年報指出水解黃豆胜肽蛋白上游依賴黃豆豆粉原物料充分供給，且最大原料供應商 2025 年占進貨淨額 39.19%；供應商名稱未揭露。
  • 大統益 1232 台股上市油脂與黃豆加工企業，為豆粉、豆粕等植物性蛋白原料產業鏈代表；未經年報確認為達邦供應商。
  • 福壽 1219 台股上市飼料、油脂與農畜相關企業，屬黃豆、飼料與植物性蛋白產業鏈代表；未經年報確認為達邦供應商。
  • 台榮 1220 台股上市飼料及相關食品原料企業，屬飼料/原料產業鏈代表；未經年報確認為達邦供應商。
Downstream
  • 甲客戶、乙客戶、丙客戶 2025 年報揭露重要客戶但以匿名方式呈現；2025 年達邦銷貨收入主要來自越南、菲律賓、韓國及台灣等亞洲地區，未揭露實名或是否掛牌。
  • 飼料廠、畜牧及水產養殖業者、區域經銷商或代理商 年報明確列為主要銷售對象；多為未揭露或未上市櫃客戶。
  • 卜蜂 1215 台股上市畜產與飼料企業，為達邦產品下游應用產業代表；未經年報確認為直接客戶。
  • 大成 1210 台股上市飼料、肉品與食品企業，為動物營養與飼料下游應用產業代表；未經年報確認為直接客戶。
  • 茂生農經 1240 台股上櫃飼料與畜牧相關企業，為下游應用產業代表；未經年報確認為直接客戶。

Competitors

  • 嘉食化 股感將其列為同屬油脂飼料相關的競爭/同業公司；實際產品線與達邦不完全相同。
  • 大成 1210 大型飼料、畜產與食品企業，屬達邦下游及廣義飼料產業同業；不等同水解黃豆胜肽蛋白直接競品。
  • 卜蜂 1215 大型飼料與畜產企業，屬廣義飼料/動物營養同業與下游客群代表。
  • 福壽 1219 飼料、油脂與農畜相關企業，屬植物性蛋白與飼料原料產業鏈同業。
  • 台榮 1220 飼料與食品原料相關上市公司，屬廣義飼料產業同業。
  • 惠勝 股感列為油脂飼料相關競爭/同業公司；需注意其業務與達邦產品差異。
  • 福懋油 1225 黃豆油脂與豆粉/豆粕相關產業鏈公司，與達邦上游原料及廣義植物性蛋白產業相關。
  • 正瀚-創 6534 農業生技公司，與達邦同屬農業科技族群，但產品聚焦不同；列為廣義農業生技同業。
  • 酪多精生物科技 未上市公司，公開資料稱其為飼料添加益生菌領導品牌，屬動物益生菌/飼料添加劑領域競爭者。
  • 國際動物營養與飼料添加劑廠商 如 DSM、Kemin、Adisseo、Zinpro、Zoetis 等，多為海外或未在台股掛牌公司，與達邦在酵素、益生菌、機能性添加劑、動物營養解決方案上有競合關係。
Sources（16）

This company profile is compiled from public sources (annual reports, filings, news and analyst reports), not finlab backtest data; the 2025–2028 outlook contains forward-looking estimates and is for reference only.

Method and limitations

  • All returns use adjusted close (etl:adj_close), already adjusted for dividends and splits.
  • Excess return is measured against the TAIEX total-return index (dividends included).
  • Valuation regime and percentile stats use an expanding own-history window (no future data).
  • Revenue-signal event dates align to the first trading day after the filing deadline, avoiding look-ahead.
  • Event samples may overlap in time; stats describe historical distribution only and are less reliable when samples are few.

This page is historical statistics for educational purposes and is not investment advice. Investing involves risk; past performance does not indicate future results. Assess and bear the risk yourself before trading.